Skip to main content

Table 3 Demographic data, the patient characteristics and ECMO data of 6 included studies with MERS outbreak (2012–2015)  

From: ECMO use in COVID-19: lessons from past respiratory virus outbreaks—a narrative review

First authorCountryStudy designStudy populationECMO pts./total pts.Age of ECMO pts. (years)PaO2/FIO2a (mmHg)MV durationa (days)ECMO duration (days)Discharged aliveb, n (%)
Choi WS [10]South KoreaRetrospective/multicentreWard and ICU13/186NANANANA8 (61.5%)
Rhee JY [11]Case review/single centreWard and ICU1/535530 (4 h)60
Al-Dorzi HM [12]Saudi ArabiaProspective/single centreHCW in ICU1/8NANANA150
Arabi YM [13]Retrospective/multicentreICU19/330NANANANA6 (31.6%)
Alshahrani MS [14]Retrospective/multicentreICU17/3545.5 (28.5–58.5)NANANA6 (35.3%)
Shalhoub S [15]Retrospective/multicentreHCW in ward and ICU9/32NANANANA4 (44.4%)
  1. Mean ± SD or median (interquartile range)
  2. HCW healthcare worker, ICU intensive care unit admission, MV mechanical ventilation, NA not applicable, pts. patients
  3. aData before ECMO support
  4. bDischarged alive of patients who underwent ECMO support